At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Inject of Autologous Adipose-derived stem cellsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Clinical Trial to Study the Feasibility and Safety of the Expanded Autologous Stem Cells Use Derived From Adipose Tissue (e-ASC) for the Local Urinary Incontinence After a Radical Prostate Cancer Surgery
Instituto de Investigación Hospital Universitario La Paz·interventional·Posted Feb 27, 2013·Updated Mar 8, 2013
In Brief
A Phase 2 clinical trial evaluating Inject of Autologous Adipose-derived stem cells for Urinary Incontinence. Completed, enrolled 10 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the feasibility and security of the autologous e-ASC for the urinary incontinence after a radical prostate cancer surgery
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Incontinence
CountriesSpain
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
Primary CompletionFeb 2013
First PostedFeb 2013
TodayJul 2026
First PostedFeb 27, 2013
Enrollment StartJul 1, 2011
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 13.3 years ago
Interventions
Inject of Autologous Adipose-derived stem cellsdrug
Inject in muscle of autologous adipose derived stem cells